KEYNOTE 181 was a phase III study in patients with advanced GOJ or esophageal cancer, showing superiority of pembrolizumab over investigator choice chemotherapy, producing prolonged median overall survival (mOS) of 9.3 vs. 6.7 months in 222 patients with PD-L1 positive tumors (CPS ≥ 10) [27]. This evidence concerns the gene CD274 and esophageal cancer.